Evidence map›Paper›PMID 31440982›Full record

ArticleAdvances in therapy2019

Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis.

Mattias Lorentzon, Jaime Branco, Maria Luisa Brandi, Olivier Bruyère, Roland Chapurlat, Cyrus Cooper, Bernard Cortet, Adolfo Diez-Perez, Serge Ferrari, Andrea Gasparik and 15 more

2 registry-linked trialsOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 60 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 6 pooled it
8.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06866561 nacompletednot on this mapstarted 2022, after this paper: background citation

The Effect of Aerobic Exercise on Bone Formation and Resorption Markers And The Quality of Life Tests in Postmenopausal Osteopenic Patients

TypeinterventionalSponsorBursa Yuksek Ihtisas Training and Research HospitalRan2022 to 2023Enrolled45ConditionsPostmenopausal OsteopeniaArmsaerobic exercise, cholecalciferol, calcium carbonate
NCT07242612 nacompletednot on this mapstarted 2025, after this paper: background citation

Determination of Selective Bone Turnover Markers and Their Association With Treatment Efficacy in Primary Postmenopausal Osteoporotic Women: A Randomized Control Trial

TypeinterventionalSponsorKhyber Medical University PeshawarRan2025 to 2026Enrolled40ConditionsOsteoporosis, Osteoporosis, PostmenopausalArmsAlendronate, Ibandronate, Risedronate, Teriparatide
3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 6 syntheses or guidelines pooled it, 103 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. From Risk to Treatment: Clinical Updates in Osteoporosis Management.International journal of rheumatic diseases · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 20 institutions in 16 countries.

Mattias LorentzonGeriatric Medicine, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Jaime BrancoCEDOC, NOVA Medical School, Medical Sciencies Faculty, NOVA University of Lisbon, Lisbon, Portugal.
Maria Luisa BrandiFirmoLab Fondazione F.I.R.M.O, University of Florence, Florence, Italy.
Olivier BruyèreWHO Collaborating Centre for Public Heath Aspects of Musculoskeletal Health and Aging, Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium.
Roland ChapurlatINSERM, UMR 1033, Université de Lyon, Hôpital E Herriot, 69437, Lyon Cedex 03, France.
Cyrus CooperMRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK.
Bernard CortetDepartment of Rheumatology and EA 44090, CHU Lille and University of Lille, 59000, Lille, France.
Adolfo Diez-PerezHospital del Mar Institue of Medical Investigation, Autonomous University of Barcelona and Biomedical Research Network on Frailty and Healthy Aging (CIBERFES), Madrid, Spain.
Serge FerrariService of Bone Diseases, Geneva University Hospital and Faculty of Medicine, 1211, Geneva 14, Switzerland.
Andrea GasparikDepartment of Public Health and Health Management, University of Medicine, Pharmacy, Science and Technology of Targu Mures, Targu Mures, Romania.
Markus HerrmannClinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria.
Niklas Rye JorgensenDepartment of Clinical Biochemistry, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
John KanisMary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia.
Jean-Marc KaufmanDepartment of Endocrinology, Ghent University Hospital, 9000, Ghent, Belgium.
Andrea LaslopScientific Office, Federal Office for Safety in Health Care, Austrian Agency for Health and Food Safety, Vienna, Austria.
Médéa LocquetDepartment of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium.
Radmila MatijevicUniversity of Novi Sad, Faculty of Medicine, Novi Sad, Serbia.
Eugene McCloskeyDepartment of Oncology and Metabolism, Centre for Integrated Research in Musculoskeletal Ageing, University of Sheffield, Sheffield, UK.
Salvatore MinisolaDepartment of Internal Medicine and Medical Disciplines, Rome University, Sapienza, Italy.
Richard PiknerDepartment of Clinical Biochemistry and Bone Metabolism, Klatovska Hospital, Klatovy, Czech Republic.
Jean-Yves ReginsterWHO Collaborating Centre for Public Health Aspects of Musculoskeletal Health and Aging, University of Liège, Liège, Belgium.
René RizzoliService of Bone Diseases, Geneva University Hospital and Faculty of Medicine, 1211, Geneva 14, Switzerland.
Pawel SzulcINSERM, UMR 1033, Université de Lyon, Hôpital E Herriot, 69437, Lyon Cedex 03, France.
Mila VlaskovskaDepartment of Pharmacology, Medical Faculty, Medical University Sofia, 2, Zdrave Str, 1431, Sofia, Bulgaria.
Etienne CavalierUniversity of Liège, CHU de Liège, Liège, Belgium. Etienne.cavalier@chu.ulg.ac.be.ORCID 0000-0003-0947-2226
University of Liège · BEUniversité Claude Bernard Lyon 1 · FRUniversity Hospital of Geneva · CHAustralian Catholic University · AUAustrian Agency for Health and Food Safety · ATCharles University · CZGhent University Hospital · BEMedical University of Graz · ATMedical University of Sofia · BGSahlgrenska University Hospital · SESapienza University of Rome · ITUniversitat Autònoma de Barcelona · ESUniversitatea de Medicină, Farmacie, Științe și Tehnologie „George Emil Palade” din Târgu Mureș · ROUniversité de Lille · FRUniversity Hospital Southampton NHS Foundation Trust · GBUniversity of Florence · ITUniversity of Lisbon · PTUniversity of Novi Sad · RSUniversity of Sheffield · GBUniversity of Southern Denmark · DK

Funding

Medical Research Council G0400491Medical Research Council MC_U147585819Medical Research Council MC_U147585824Medical Research Council MC_U147585827Medical Research Council MC_UP_A620_1014Medical Research Council MC_UU_12011/1Medical Research Council MR/P020941/1
6 · The paper itself

Abstract

introductionIncreased biochemical bone turnover markers (BTMs) measured in serum are associated with bone loss, increased fracture risk and poor treatment adherence, but their role in clinical practice is presently unclear. The aim of this consensus group report is to provide guidance to clinicians on how to use BTMs in patient evaluation in postmenopausal osteoporosis, in fracture risk prediction and in the monitoring of treatment efficacy and adherence to osteoporosis medication.

methodsA working group with clinical scientists and osteoporosis specialists was invited by the Scientific Advisory Board of European Society on Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO).

resultsSerum bone formation marker PINP and resorption marker βCTX-I are the preferred markers for evaluating bone turnover in the clinical setting due to their specificity to bone, performance in clinical studies, wide use and relatively low analytical variability. BTMs cannot be used to diagnose osteoporosis because of low sensitivity and specificity, but can be of value in patient evaluation where high values may indicate the need to investigate some causes of secondary osteoporosis. Assessing serum levels of βCTX-I and PINP can improve fracture prediction slightly, with a gradient of risk of about 1.2 per SD increase in the bone marker in addition to clinical risk factors and bone mineral density. For an individual patient, BTMs are not useful in projecting bone loss or treatment efficacy, but it is recommended that serum PINP and βCTX-I be used to monitor adherence to oral bisphosphonate treatment. Suppression of the BTMs greater than the least significant change or to levels in the lower half of the reference interval in young and healthy premenopausal women is closely related to treatment adherence.

conclusionIn conclusion, the currently available evidence indicates that the principal clinical utility of BTMs is for monitoring oral bisphosphonate therapy.

Indexed as

AlgorithmsAgedAged, 80 and overBiomarkersBone DensityBone Density Conservation AgentsBone RemodelingDiphosphonatesFemaleFollow-Up StudiesHumansMiddle AgedOsteoporosis, PostmenopausalReference ValuesTreatment OutcomeBiomarkersBone Density Conservation AgentsDiphosphonatesAlgorithmBoneBone biomarkerCTXOsteoporosisP1NPRheumatology

Identifiers

PMID31440982
PMCPMC6822833
OpenAlexW2969635189

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.